Welcome to our dedicated page for Stoke Therapeutics SEC filings (Ticker: STOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Stoke Therapeutics, Inc. (Nasdaq: STOK) SEC filings page on Stock Titan provides access to the company’s official U.S. regulatory disclosures. As a Nasdaq Global Select Market issuer, Stoke files current reports, annual reports, and other documents that describe its financial condition, governance, and progress in developing RNA-based medicines such as zorevunersen for Dravet syndrome and STK-002 for Autosomal Dominant Optic Atrophy (ADOA).
Current reports on Form 8-K document material events, including quarterly financial results, clinical and collaboration milestones, and changes in executive leadership. For example, Stoke has used Form 8-K to announce results of operations, disclose the appointment of its Chief Executive Officer and related employment and severance agreements, and furnish press releases about the initiation and progress of the global Phase 3 EMPEROR study of zorevunersen and the Phase 1 OSPREY study of STK-002.
Amended current reports on Form 8-K/A provide additional detail or updates on previously reported items, such as the company’s decisions regarding the frequency of advisory shareholder votes on executive compensation. These filings offer insight into Stoke’s corporate governance practices and board decisions.
Through Stock Titan, investors can also track periodic filings such as Forms 10-K and 10-Q when available, which typically include detailed discussions of Stoke’s TANGO antisense platform, its rare disease pipeline, collaboration agreements, and risk factors. Form 4 and related insider transaction filings, when present, can help users monitor equity awards and share transactions by directors and officers.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping users quickly understand the significance of items such as clinical trial disclosures, collaboration terms, compensation arrangements, and shareholder voting outcomes. Real-time updates from the SEC’s EDGAR system ensure that new STOK filings, including 10-K, 10-Q, 8-K, and Form 4 submissions, are surfaced promptly for further review and analysis.
Ticho Barry reported acquisition or exercise transactions in this Form 4 filing.
Stoke Therapeutics’ chief medical officer, Barry Ticho, reported equity awards rather than open‑market trades. He was granted options to purchase 60,000 shares of common stock and 40,000 restricted stock units. The option vests monthly over four years starting March 15, 2026, while the RSUs vest in four annual tranches beginning February 15, 2027, in each case conditioned on continued service.
Stoke Therapeutics reported that Chief Executive Officer Ian F. Smith received new equity awards in the form of options and restricted stock units. He was granted 193,000 employee stock options with an exercise right to buy company shares, which vest monthly over four years starting March 15, 2026, contingent on continued service. He also received 129,000 restricted stock units, each representing a right to one share of common stock, vesting in four annual tranches beginning February 15, 2027, also subject to his continued service.
Leggett Thomas reported acquisition or exercise transactions in this Form 4 filing.
Stoke Therapeutics, Inc. reported that its Chief Financial Officer, Thomas Leggett, received new equity awards. He was granted an option to buy 60,000 shares of common stock at no cost on the grant date, which will vest in monthly installments over four years starting March 15, 2026, contingent on continued service. He also received 40,000 restricted stock units, each representing one share of common stock, vesting in four equal annual installments beginning February 15, 2027, also conditioned on his continued service.
Stoke Therapeutics reported that Chief Patient Officer Jason Hoitt received new equity awards. He was granted employee stock options covering 72,000 shares at an exercise price of
The option award vests monthly over four years, beginning with 1/48 of the total on
Stoke Therapeutics, Inc. reported that its General Counsel and Corporate Secretary, Allan Jonathan, received new equity awards. On February 17, 2026, he was granted an option to buy 53,000 shares of common stock at an exercise price of $0.00 per share and 35,000 restricted stock units (RSUs).
The option vests as to 1/48 of the total award on March 15, 2026, with an additional 1/48 vesting on each monthly anniversary, as long as he continues serving the company. Each RSU represents the right to receive one share of common stock, with the RSU award vesting in four equal annual installments beginning on February 15, 2027, also subject to continued service.
Baker Bros. Advisors filed an amended Schedule 13G reporting beneficial ownership of 3,336,697 shares of Stoke Therapeutics, Inc. common stock, representing 5.8% of the outstanding shares as of October 31, 2025. These shares are held through funds 667, L.P. and Baker Brothers Life Sciences, L.P.
The filing notes 667, L.P. holds 283,443 shares (0.5% of the class) and Baker Brothers Life Sciences, L.P. holds 3,053,254 shares (5.3% of the class). It also describes pre-funded warrants capped by a 4.99% beneficial ownership limit, adjustable up to 19.99% with a 61-day notice period, which currently prevents exercise.
FMR LLCStoke Therapeutics, Inc.December 31, 20255,600,920 shares9.8%
FMR LLC has sole voting power over 5,590,109 shares5,600,920 shares
Stoke Therapeutics, Inc. entered into a new long-term lease for its corporate headquarters and laboratory space at 245 Fifth Avenue, Waltham, Massachusetts. The lease covers approximately 98,500 square feet and is scheduled to run through March 31, 2038, giving the company a stable base for its operations.
The agreement includes two options to extend the term by an additional five years each at then-prevailing market rates, which could keep the company in the facility well beyond 2038. Aggregate estimated base rent over the initial term is approximately $85.5 million, and the company will provide a $3 million security deposit via an irrevocable standby letter of credit that may be reduced over time under the lease terms.
Stoke Therapeutics filed an update describing a new press release about its Phase 3 EMPEROR study of zorevunersen for Dravet syndrome and its cash position. The company expects to report approximately $391.7 million in cash, cash equivalents and marketable securities as of December 31, 2025, and says that, together with eligible proceeds from its Biogen collaboration, this is anticipated to fund operations into 2028. The press release also updates timelines for completion of enrollment and Phase 3 data readout for EMPEROR and provides additional detail on the trial design. Management stresses that these financial figures are preliminary, unaudited estimates that may change once year-end closing procedures and the audit are completed, and highlights typical clinical, regulatory, collaboration and macroeconomic risks in its forward-looking statements.